The GLP-1 receptor agonist exendin-4 prevented closure of the ductus arteriosus in newborn rats by relaxing the vessel and blocking tissue remodeling through PKA signaling.
DA closure prevented at 2 hours post-birthWhile control rats showed spontaneous ductus arteriosus closure within two hours of birth, exendin-4-treated rats maintained an open vessel with reduced intimal thickening.
What the researchers found
Exendin-4 (Ex-4), a GLP-1 receptor agonist, maintained ductus arteriosus (DA) patency in neonatal rats by preventing spontaneous closure that normally occurs within two hours after birth. Ex-4 reduced intimal thickening, attenuated oxygen-induced vasoconstriction in isolated DA rings, and inhibited PDGF-BB-induced proliferation, migration, ROS production, and calcium mobilization in DA smooth muscle cells. All of these effects were blocked by H89, a PKA inhibitor, establishing the GLP-1R/PKA pathway as the mechanism of action.
Why it matters
Patent ductus arteriosus (PDA) is a common condition in premature infants where the blood vessel connecting the aorta to the pulmonary artery fails to close after birth — or in some cases, needs to be kept open therapeutically. This study reveals a new mechanism through which GLP-1 receptor agonists could be used to manage DA patency, potentially offering a novel pharmacological approach for neonates with congenital heart conditions.
How the study worked
The researchers first confirmed GLP-1 receptor expression in neonatal rat DA tissue. They then tested exendin-4 in vivo by observing DA closure in neonatal rats at two hours after birth, comparing treated animals to controls. Ex vivo experiments measured oxygen-induced vasoconstriction in isolated DA rings. In vitro experiments on DA smooth muscle cells assessed proliferation, migration, ROS production, calcium mobilization, and signaling pathways (MAPK, Akt, Nrf2), with and without the PKA inhibitor H89.
Who was studied
Neonatal Sprague-Dawley rats and isolated DA smooth muscle cells
What this study cannot tell us
This study was conducted entirely in neonatal rats, so the findings may not directly translate to human neonates. The abstract does not report specific quantitative results (effect sizes, p-values) for any of the experiments. The PKA pathway was identified using a single pharmacological inhibitor (H89) rather than genetic approaches, which could be less specific.
How to read the evidence
This is a preclinical animal study using neonatal rats with in vivo, ex vivo, and in vitro experiments. While the multi-level approach strengthens mechanistic understanding, animal studies are early-stage evidence and do not directly demonstrate clinical applicability in humans.
When this study was published
Published in 2024, this is a recent preclinical study. The findings are novel and have not yet been tested in human clinical trials.
The bigger picture
GLP-1 receptor agonists are best known for treating diabetes and obesity, but this study adds to growing evidence that they have cardiovascular effects beyond metabolic control. Discovering that the GLP-1R/PKA pathway can regulate ductus arteriosus patency opens an entirely new therapeutic application in neonatal cardiology, potentially expanding the clinical utility of this well-studied drug class.
Questions still open
- Can exendin-4 or other GLP-1 receptor agonists safely maintain ductus arteriosus patency in human neonates?
- How does the GLP-1R/PKA pathway interact with prostaglandin signaling, the current standard for maintaining DA patency?
- Could GLP-1 receptor agonists inadvertently affect DA closure in newborns of mothers taking these drugs during pregnancy?
Common questions
What is the ductus arteriosus and why would you want to keep it open?
Is exendin-4 the same as the GLP-1 drugs used for diabetes and weight loss?
Read the original research
Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.
European journal of pharmacology, 985, 177106
Citation
Liu, Yi-Ching; Tseng, Yu-Hsin; Wu, Yen-Hsien; Tong, Lorraine; Tsai, Siao-Ping; Huang, Shang-En; Wu, Bin-Nan; Lo, Shih-Hsing; Chen, I-Chen; Dai, Zen-Kong; Yeh, Jwu-Lai; Hsu, Jong-Hau. (2024). Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.. European journal of pharmacology, 985, 177106. https://doi.org/10.1016/j.ejphar.2024.177106